Masateru Okazaki1, Hisanori Kobayashi2, Yutaka Ishii2, Masayoshi Kanbori3, Tsutomu Yajima4. 1. Immunology Department, Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan. mokazak1@its.jnj.com. 2. Immunology Department, Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan. 3. Japan Safety and Surveillance Division, Research and Development Division, Janssen Pharmaceutical K.K., Tokyo, Japan. 4. Biostatistics Department, Research and Development Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
Abstract
INTRODUCTION: The aim of this study was to investigate real-world treatment patterns for use of golimumab and concomitant medications in Japanese patients with rheumatoid arthritis. METHODS: This study was a post hoc retrospective analysis from post-marketing surveillance data on 2350 Japanese patients with moderate/severe rheumatoid arthritis who received golimumab for 24 weeks. The study population was divided based on initiation treatment or dose adjustment patterns with golimumab, methotrexate, or oral glucocorticoids. RESULTS: Logistic regression analysis revealed that the baseline factors associated with administration of golimumab (100 mg) were higher body weight, failure of prior biological therapy (bio-failure), no previous methotrexate use, and respiratory disease, while previous methotrexate use and absence of renal impairment or respiratory disease were associated with concomitant methotrexate therapy, and previous glucocorticoid use was associated with concomitant glucocorticoid therapy. The following associations were identified with regard to dose adjustment during treatment: bio-failure, no previous methotrexate use, previous csDMARDs use, presence of respiratory disease, allergy history, and higher CRP for golimumab dose escalation; shorter disease duration, previous GC, and no previous methotrexate use for methotrexate dose escalation; no prior biological therapy and renal impairment for methotrexate dose reduction; no previous GC use for glucocorticoid dose escalation; and absence of Steinbrocker's stage II/III/IV, absence of Steinbrocker's class II, no bio-failure, and no previous csDMARDs use for glucocorticoid dose reduction. CONCLUSIONS: This study revealed that various baseline factors were associated with initiation of treatment and dose adjustment of golimumab, methotrexate, or oral glucocorticoids, reflecting both the treatment strategies of physicians for improving RA symptoms and/or reducing adverse events. FUNDING: Janssen Pharmaceutical K.K. and Mitsubishi Tanabe Pharma Corporation.
INTRODUCTION: The aim of this study was to investigate real-world treatment patterns for use of golimumab and concomitant medications in Japanese patients with rheumatoid arthritis. METHODS: This study was a post hoc retrospective analysis from post-marketing surveillance data on 2350 Japanese patients with moderate/severe rheumatoid arthritis who received golimumab for 24 weeks. The study population was divided based on initiation treatment or dose adjustment patterns with golimumab, methotrexate, or oral glucocorticoids. RESULTS: Logistic regression analysis revealed that the baseline factors associated with administration of golimumab (100 mg) were higher body weight, failure of prior biological therapy (bio-failure), no previous methotrexate use, and respiratory disease, while previous methotrexate use and absence of renal impairment or respiratory disease were associated with concomitant methotrexate therapy, and previous glucocorticoid use was associated with concomitant glucocorticoid therapy. The following associations were identified with regard to dose adjustment during treatment: bio-failure, no previous methotrexate use, previous csDMARDs use, presence of respiratory disease, allergy history, and higher CRP for golimumab dose escalation; shorter disease duration, previous GC, and no previous methotrexate use for methotrexate dose escalation; no prior biological therapy and renal impairment for methotrexate dose reduction; no previous GC use for glucocorticoid dose escalation; and absence of Steinbrocker's stage II/III/IV, absence of Steinbrocker's class II, no bio-failure, and no previous csDMARDs use for glucocorticoid dose reduction. CONCLUSIONS: This study revealed that various baseline factors were associated with initiation of treatment and dose adjustment of golimumab, methotrexate, or oral glucocorticoids, reflecting both the treatment strategies of physicians for improving RA symptoms and/or reducing adverse events. FUNDING: Janssen Pharmaceutical K.K. and Mitsubishi Tanabe Pharma Corporation.
Authors: G S Alarcón; J M Kremer; M Macaluso; M E Weinblatt; G W Cannon; W R Palmer; E W St Clair; J S Sundy; R W Alexander; G J Smith; C A Axiotis Journal: Ann Intern Med Date: 1997-09-01 Impact factor: 25.391
Authors: Désirée van der Heijde; Lars Klareskog; Vicente Rodriguez-Valverde; Catalin Codreanu; Horatiu Bolosiu; Jose Melo-Gomes; Jesus Tornero-Molina; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad Journal: Arthritis Rheum Date: 2006-04
Authors: Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green Journal: Arthritis Rheum Date: 2006-01
Authors: Zhenhua Xu; Thuy Vu; Howard Lee; Chuanpu Hu; Jie Ling; Hong Yan; Daniel Baker; Anna Beutler; Charles Pendley; Carrie Wagner; Hugh M Davis; Honghui Zhou Journal: J Clin Pharmacol Date: 2009-07-17 Impact factor: 3.126
Authors: Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G Krueger; Dafna Gladman; Juan Gomez-Reino; Kim Papp; Julie Zrubek; Surekha Mudivarthy; Michael Mack; Sudha Visvanathan; Anna Beutler Journal: Arthritis Rheum Date: 2009-04
Authors: Sofie H M Manders; Mart A F J van de Laar; Sanne A A Rongen-van Dartel; Reinhard Bos; Henk Visser; Herman L Brus; Tim Jansen; Harald E Vonkeman; Piet L C M van Riel; Wietske Kievit Journal: RMD Open Date: 2015-10-08
Authors: Suepattra G May; Caroline Huber; Meaghan Roach; Jason Shafrin; Wade Aubry; Darius Lakdawalla; John M Kane; Felicia Forma Journal: J Med Internet Res Date: 2021-02-03 Impact factor: 5.428